Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Scil Technology Announces Positive Results in Preclinical Study of its Lead Dental Bone Augmentation


This study compared the osteoinductive bone substitute MD05 with conventional bone substitutes in the reconstruction of defects in the cranio-maxillofacial region. The results demonstrated that MD05 was highly superior to the conventional bone substitutes with respect to the formation of new bone and bone marrow and can be favourably positioned in the dental bone augmentation market:
 MD05 has an efficacy superior to autologous bone in a 1:1 mixture with beta-TCP and does not require a second surgical procedure.
 MD05 shows a superior efficacy compared to commercially available competitor products.
 MD05 is safe, the product does not induce excessive bone growth.
MD05 is an osteoinductive bone substitute, which is comprised of the synthetic carrier, beta-tricalciumphosphate coated with recombinant human growth and differentiation factor-5.
Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“This biomaterial will be the first synthetic, fully resorbable, compression resistant dental bone augmentation product combining osteoconductive and osteoinductive properties to enter the clinic.”
– ends –

About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, bone trauma, joint cartilage defects and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.
For more information please visit: http://www.scil.com

Notes for editors
About MD05
MD05 has two components: a synthetic inorganic carrier, ß -Tricalcium phosphate (ß-TCP), and a recombinant growth factor - rhGDF-5, a naturally occurring human protein that acts by promoting the growth of bone. ß -TCP is a synthetic calcium-phosphate biomaterial which acts as a scaffold and space-maintainer for new bone ingrowth. It is a well accepted biomaterial for bone augmentation in dentistry and orthopaedic surgery such as e.g. spinal fusion. Scil uses a proprietary coating technology for the non-covalent association of rhGDF-5 with the surface of the ß -TCP-granules.
About this preclinical study
This study compared the osteoinductive bone substitute MD05 with conventional bone substitutes in the reconstruction of defects in the cranio-maxillofacial region. Because of its biological inertness, the calvarium (the upper jaw and skull) is the principal site for analysing the performance of bone-regeneration materials.
Analysis of the results revealed that MD05 achieved the best macroscopic performance in terms of skull/implant attachment and solidity of the material. Bone repair assessed histomorphometrically was more than five times greater with MD05 compared to the competitor products and was mostly complete after six weeks. Also, in contrast to the other treatments, bone repair was associated with the formation of normal bone marrow and substantial decrease of fibrous tissue,
In conclusion, MD05 was vastly superior to the conventional bone substitutes with respect to the formation of new bone and bone marrow. Using MD05, complete osseous bridging of the full-thickness critical-.size defects in the rat calvarium was achieved after 6 weeks in the absence of excessive bone formation.


Publisher Contact Information:

Scil Technology GmbH
+49 (0)89 85651824
i.staatz@scil.com

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.

Data


26,126
Tech investments
From our Online Data Service
16,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.